Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Osteosarcoma is a complex cancer with limited targeted therapies due to genomic heterogeneity.
• Epigenetic dysregulation is increasingly recognized as a driver of cancer complexity and heterogeneity.

Purpose of the Study:

• To investigate the role of epigenetic mechanisms in driving distinct osteosarcoma subtypes.
• To identify and characterize cellular states within osteosarcoma based on epigenetic profiles.
• To explore the therapeutic implications of these identified subtypes.

Main Methods:

• Chromatin accessibility profiling to identify distinct cell states.
• Multiomic single-cell analysis to define core regulatory circuitries.
• Utilizing patient-derived xenograft models to assess differential drug responses.

Main Results:

• Identification of two osteosarcoma cell states: early osteoblast-derived (EOD) and late osteoblast-derived (LOD).
• EOD and LOD states are characterized by distinct transcription factor profiles related to bone development.
• These cell states co-exist within tumors and exhibit differential responses to therapies in preclinical models.

Conclusions:

• Epigenetic heterogeneity defines distinct osteosarcoma subtypes with therapeutic relevance.
• Understanding these epigenetic subtypes is crucial for developing effective combination therapies for osteosarcoma.
• This work highlights the potential of epigenetic subtyping in complex cancers.